When was Zymeworks founded?

Zymeworks was founded in 2003 and raised its 1st funding round 2 years after it was founded.

Where is Zymeworks located?

Zymeworks is headquartered in Vancouver, Canada. It is registered at Seattle, Washington.

How many employees does Zymeworks have?

As of Apr 30, 2026, the latest employee count at Zymeworks is 277.

Is Zymeworks a funded company?

Zymeworks is a funded company, having raised a total of $146M across 15 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 2005.

When was the latest funding round of Zymeworks?

Zymeworks' latest funding was a $***** Post IPO round on Dec 26, 2023, with participation from 1 investor.

What is the annual revenue of Zymeworks?

Annual revenue of Zymeworks is $106M as on Dec 31, 2025.

Where does Zymeworks rank among its competitors?

Zymeworks ranks 21st amongst 3209 active competitors, of which 1102 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of Zymeworks?

Zymeworks' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

Zymeworks - 2026 Company Profile, Team, Funding, Competitors & Financials

Zymeworks is a public company based in Vancouver (Canada), founded in 2003. It operates as a Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer. Zymeworks has raised $146M in funding from investors like Advanced Biotechnologies Venture Fund, CTI Life Sciences Fund and Fonds de solidarite FTQ. The company has 3209 active competitors, including 1102 funded and 767 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma.

Company Details

Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer. The company’s Azymetric and AlbuCORE platforms, and its proprietary ZymeCAD structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications.

Website: www.zymeworks.com/
Social
Registered Address: Seattle, Washington

Key Metrics

Founded Year

2003

Location

Vancouver, Canada

Stage

Public

Total Funding

$146M in 15 rounds

Latest Funding Round

Post IPO, Dec 26, 2023, $*****

Investors

Advanced Biotechnologies Venture Fund & 17 more

Ranked

21^st among 3209 active competitors

Annual Revenue

$106M as on Dec 31, 2025

Employee Count

277 as on Apr 30, 2026

Investment & Acquisitions

Kairos Therapeutics

Similar Companies

Jazz Pharmaceuticals & 3019 more

Exit Details

Public

View Zymeworks' full profile

Zymeworks is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ZYMEWORKS BIOPHARMACEUTICALS, INC. CIN: 472569713 , United States, Active	Dec 26, 999	-	76 (As on Dec 31, 2024)	-
Zymeworks Inc. CIN: 1403752 , United States, Active	Jun 29, 2022	$106M (As on Dec 31, 2025)	-	-

Zymeworks got listed on Apr 28, 2017.

Click here to take a look at Zymeworks's IPO in detail

Zymeworks has raised a total funding of $146M over 15 rounds. Its first funding round was on May 2005. Its latest funding round was a Post IPO round on Dec 26, 2023 for $*****. 1 investor participated in its latest round. Zymeworks has 17 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Zymeworks:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 26, 2023	3934920	Post IPO	6385340	8480653	9008539	7072712
Jan 08, 2016	5478105	Series A	3251920	7405224	3300567	8573709
Feb 27, 2015	7169994	Series A	8015902	2775008	7138156	9701883

Access funding benchmarks and valuations. Sign up today!

View details of Zymeworks's funding rounds and investors

Zymeworks' employee count trend

Zymeworks has 277 employees as of Apr 26. Here is Zymeworks's employee count trend over the years:

Uncover Zymeworks' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zymeworks include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Here is the list of Top 10 competitors of Zymeworks, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Omega Funds & 17 others	75/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, Bezos Expeditions & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
21st	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	Teralys Capital, Celgene & 16 others	71/100